10 Stocks Lead Wednesday’s Charge, Mirror Broader Gains

3. Moderna Inc. (NASDAQ:MRNA)

Moderna shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as investors gobbled up shares in the company following an announcement that it anticipates the release of a personalized cancer vaccine, which it was developing with Merck Co., by 2027.

Efficacy of the vaccine is currently at 50 percent, but the company was looking to surpass such target, although the actual efficacy rate will only be determined after further case accrual.

At present, the company is conducting a late-stage trial for a skin cancer vaccine, which, according to MRNA President Stephen Hogek, could rapidly realize revenues.

A phase three study for the vaccine had been enrolled on September 2024.

Last month, MRNA also surged following news that a new bat coronavirus carries the risk of animal-to-human transmission, fueling optimism of higher vaccine sales.